Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O4S.C6H14N2O2 |
| Molecular Weight | 495.592 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(O)=O.[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CCC=CC3)C(O)=O
InChI
InChIKey=NTKRAGMAXIPNKX-SSDGIDNNSA-N
InChI=1S/C16H19N3O4S.C6H14N2O2/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9;7-4-2-1-3-5(8)6(9)10/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23);5H,1-4,7-8H2,(H,9,10)/t10-,11-,15-;5-/m10/s1
| Molecular Formula | C6H14N2O2 |
| Molecular Weight | 146.1876 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C16H19N3O4S |
| Molecular Weight | 349.405 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antimicrobial resistance of bacterial organisms isolated from rats. | 2001 Dec |
|
| Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
| Comparison of local povidone-iodine antisepsis with parenteral antibacterial prophylaxis for prevention of infective complications of TURP: a prospective randomized controlled study. | 2002 Mar |
|
| [Empirical therapy of peritonitis in peritoneal dialysis patients--it is reasonable to use a new therapeutic schedule?]. | 2002 Nov |
|
| H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine. | 2005 Jan |
|
| Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography. | 2005 Mar-Apr |
|
| Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection. | 2005 Oct 21 |
|
| Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. | 2005 Sep 14 |
|
| Properties and active substance release kinetics from gelatin-alginate matrices. | 2006 |
|
| [Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases]. | 2006 Apr |
|
| A case of inadvertent anterior chamber and corneal stromal injection with antibiotics during cataract operation. | 2006 Dec |
|
| Microplate assay for inhibitors of the transpeptidase activity of PBP1b of Escherichia coli. | 2006 Dec |
|
| Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction. | 2007 Jun 5 |
|
| Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. | 2007 Oct |
|
| Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. | 2008 Apr 16 |
|
| A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
| Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 Dec |
|
| Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. | 2008 Dec |
|
| Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. | 2008 Feb |
|
| [Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial]. | 2008 Jan 15 |
|
| Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD. | 2008 May-Jun |
|
| Studies on diseased freshwater prawn Macrobrachium rosenbergii infected with Vibrio vulnificus. | 2008 Sep 1 |
|
| Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. | 2009 |
|
| A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application. | 2009 Aug |
|
| [Analysis of multiple cephalosporins in blood and urine by HPLC]. | 2009 Dec |
|
| [Kneading and dispersing manipulation in treatment of early-stage acute mastitis: a randomized controlled trial]. | 2009 Dec |
|
| [Study of cefadroxil and cephradine charge transfer process by fluorescence quenching method]. | 2009 Feb |
|
| Lack of interaction between the peptidomimetic substrates captopril and cephradine. | 2009 Mar |
|
| Study on the binding behavior of lysozyme with cephalosporin analogues by fluorescence spectroscopy. | 2009 Sep |
|
| Traumatic optic neuropathy accompanying orbital grease gun injury. | 2010 Apr |
|
| Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles. | 2010 Apr 15 |
|
| Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. | 2010 Jan |
|
| Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent. | 2010 Jan |
|
| Uropathogen resistance to antibiotic prophylaxis in urinary tract infections. | 2010 Jun |
|
| Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia. | 2010 Mar-Apr |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:24:29 UTC 2023
by
admin
on
Fri Dec 15 15:24:29 UTC 2023
|
| Record UNII |
41BJN3H129
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
68641-66-7
Created by
admin on Fri Dec 15 15:24:29 UTC 2023 , Edited by admin on Fri Dec 15 15:24:29 UTC 2023
|
PRIMARY | |||
|
71587237
Created by
admin on Fri Dec 15 15:24:29 UTC 2023 , Edited by admin on Fri Dec 15 15:24:29 UTC 2023
|
PRIMARY | |||
|
41BJN3H129
Created by
admin on Fri Dec 15 15:24:29 UTC 2023 , Edited by admin on Fri Dec 15 15:24:29 UTC 2023
|
PRIMARY | |||
|
DTXSID90218733
Created by
admin on Fri Dec 15 15:24:29 UTC 2023 , Edited by admin on Fri Dec 15 15:24:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |